ArticleFrontiers in physiology2025
Ketogenic diet-induced changes in methylation status and neuropeptide signaling: relationships between S-adenosylmethionine (AdoMet), orexin-A, and metabolic health.
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: S-Adenosylmethionine (AdoMet) is the principal methyl donor in numerous biochemical reactions, regulating lipid and glucose metabolism, inflammatory pathways, and neurotransmitter synthesis. Orexin-A, a hypothalamic neuropeptide involved in arousal, feeding behavior, and energy expenditure, plays a crucial role in metabolic homeostasis. Emerging evidence suggests potential crosstalk between methylation pathways and orexinergic signaling; however, this interaction has not been explored in the context of nutritional ketosis. This study aimed to evaluate the effects of a structured ketogenic dietary intervention on circulating AdoMet, Orexin-A, and key metabolic parameters. Methods: Twenty-one adults (11 males, 10 females) were recruited from the Unit of Dietetics, Sports Medicine, and Psychophysical Wellbeing, University Hospital "L. Vanvitelli" of Naples, Italy. Participants followed a ketogenic diet for 8 weeks. Anthropometric measurements, body composition, fasting biochemical parameters, AdoMet, and Orexin-A levels were assessed at baseline (T0) and post-intervention (T1). Paired t-tests were used to analyze within-subject changes, and linear regression analyses explored correlations between AdoMet and metabolic variables. The study was approved by the Ethics Committee of the University of Campania "Luigi Vanvitelli" (Protocol No. 0003232/I, 01/02/2023). Results: After 8 weeks, participants exhibited significant reductions in body weight, BMI, visceral adipose tissue, total cholesterol, fasting glycemia, triglycerides, and HbA1c (all p < 0.05). Circulating AdoMet (-75.7%) and Orexin-A (-7.2%) levels also decreased significantly. AdoMet levels positively correlated with body weight, BMI, visceral adipose tissue, total cholesterol, fasting glycemia, triglycerides, HbA1c, and notably Orexin-A (R Discussion: The ketogenic diet significantly improved anthropometric and metabolic parameters while concurrently reducing AdoMet and Orexin-A levels. The strong positive correlation between AdoMet and Orexin-A suggests an interaction between methylation status and neuropeptide signaling during metabolic adaptation to ketosis. These findings highlight AdoMet as a potential integrated biomarker of metabolic health and emphasize the relevance of neuro-metabolic regulation in dietary interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.